Latest Intelligence on Pharmaceuticals and Healthcare in Brazil

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Ache: Brazilian domestic player to step up its game

Ache, the Brazilian branded generics specialist, has announced its intention to pursue an initial public offering in order to raise capital and remain competitive. The move reflects the growing interest in Brazil's burgeoning pharmaceutical market, and is essential if Ache is to compete with the considerable growth in both domestic and international players in the country.

Published By Datamonitor
17 Nov 2010
CommentWire
CommentWire

Bayer: choosing Dendrite for salesforce support

Published By Datamonitor
13 Jun 2001
Expert View
Expert View

Big Pharma rushing for foothold in emerging markets despite challenges

Faced with dwindling growth rates in the US and Europe, drug companies are turning their attention towards emerging pharmaceutical markets where recent economic booms have fuelled double-digit growth. However, although the patient potential of these countries is enormous, foreign pharmaceutical companies are currently tapping into only a fraction of the market.

Published By Datamonitor
13 Mar 2008
Expert View
Expert View

Brazilian patent threat poses challenge to big pharma

Relying on its reputation as a world leader in HIV/AIDS drug pricing negotiations, Brazil is threatening to disregard patents unless Abbott Laboratories, Gilead Sciences and Merck & Co. allow it to produce generic versions of their four leading AIDS drugs. Datamonitor's Mar Ferrero investigates the likely ramifications of such a move...

Published By Datamonitor
23 Jun 2005
Expert View
Expert View

Breaking Merck patent may drive investment away from Brazil

Brazil's government will bypass Merck's patent on HIV drug Sustiva in order to manufacture this best-selling NNRTI as a lower-priced generic. Although this will increase therapy-access for many HIV/AIDS patients, it will intensify concerns over parallel imports into Western markets, according to Datamonitor's HIV analyst Lisette Oversteegen.

Published By Datamonitor
09 May 2007
CommentWire
CommentWire

GlaxoSmithKline: cutting the cost of HIV drugs

GlaxoSmithKline's fifth round of price cuts since 1997 includes 14 HIV drugs reduced by an average of 21%. The biggest reduction is a 40% cut in the price of Ziagen, a first and second line AIDS treatment. With the use of compulsory licenses becoming more frequent among developing countries, GSK will hope that such price cuts appease governments and prevent their patents being bypassed.

Published By Datamonitor
21 Feb 2008
CommentWire
CommentWire

GSK: another price-reduction deal in emerging markets

As part of its ongoing attempts to penetrate the emerging markets, GlaxoSmithKline has signed an innovative pneumococcal vaccines deal in Brazil, which also includes a technology transfer and R&D investment. As well as boosting the pharma giant's volume in this rapidly growing and commercially attractive market, the deal is expected to increase access to vaccines in the country.

Published By Datamonitor
29 Sep 2009
CommentWire
CommentWire

HIV drugs: patent disputes escalate

Published By Datamonitor
28 Aug 2001
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
ResearchWire
ResearchWire

Trauma devices: Chinese market to grow 168%

Published By Datamonitor
12 Mar 2002

« | 1 | 2 | » »|

No help is available.